CN118660712A - 肝脂肪变性的预防或治疗 - Google Patents

肝脂肪变性的预防或治疗 Download PDF

Info

Publication number
CN118660712A
CN118660712A CN202280079735.0A CN202280079735A CN118660712A CN 118660712 A CN118660712 A CN 118660712A CN 202280079735 A CN202280079735 A CN 202280079735A CN 118660712 A CN118660712 A CN 118660712A
Authority
CN
China
Prior art keywords
species
anaerobic
use according
bifidobacterium
lactobacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280079735.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·G·霍勒博姆
马克斯·纽多普
威廉·门德尔特·德沃斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amsterdam University Medical Center Foundation
Kales Life Science Intellectual Property Co., Ltd.
Original Assignee
Amsterdam University Medical Center Foundation
Caelus Pharmaceuticals BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amsterdam University Medical Center Foundation, Caelus Pharmaceuticals BV filed Critical Amsterdam University Medical Center Foundation
Publication of CN118660712A publication Critical patent/CN118660712A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202280079735.0A 2021-12-03 2022-11-30 肝脂肪变性的预防或治疗 Pending CN118660712A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2030011 2021-12-03
NL2030011A NL2030011B1 (en) 2021-12-03 2021-12-03 Prevention or treatment of hepatic steatosis
PCT/EP2022/083885 WO2023099579A1 (en) 2021-12-03 2022-11-30 Prevention or treatment of hepatic steatosis

Publications (1)

Publication Number Publication Date
CN118660712A true CN118660712A (zh) 2024-09-17

Family

ID=80448857

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280079735.0A Pending CN118660712A (zh) 2021-12-03 2022-11-30 肝脂肪变性的预防或治疗

Country Status (7)

Country Link
US (1) US20250025517A1 (enExample)
EP (1) EP4440588A1 (enExample)
JP (1) JP2024545441A (enExample)
CN (1) CN118660712A (enExample)
NL (1) NL2030011B1 (enExample)
TW (1) TW202332457A (enExample)
WO (1) WO2023099579A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025077370A1 (zh) * 2023-10-12 2025-04-17 雷文虎克生物技术股份有限公司 艾克曼嗜黏蛋白菌及其用于预防非酒精性脂肪肝炎的用途
WO2025229145A1 (en) 2024-05-02 2025-11-06 Stichting Amsterdam UMC Desulfovibrio piger species for prevention or treatment of hepatic steatosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3140096A1 (en) * 2019-05-21 2020-11-26 Pendulum Therapeutics, Inc. Methods and compositions for treating liver disorders
WO2021204719A1 (en) 2020-04-07 2021-10-14 Wholefiber Holding B.V. Particles comprising inulin for use as medicament or supplement

Also Published As

Publication number Publication date
NL2030011B1 (en) 2023-06-20
US20250025517A1 (en) 2025-01-23
WO2023099579A1 (en) 2023-06-08
EP4440588A1 (en) 2024-10-09
TW202332457A (zh) 2023-08-16
JP2024545441A (ja) 2024-12-06

Similar Documents

Publication Publication Date Title
CN111603488B (zh) 阿克曼氏菌属用于治疗代谢病症的用途
JP2022000040A (ja) 代謝障害を処置するための低温殺菌アッカーマンシアの使用
JP6843140B2 (ja) 肥満および関連する代謝障害を処置するためのビフィドバクテリウム・ロングム
JP2024516950A (ja) ラクトバチルス・ロイテリ及びその使用、組成物、医薬品及び食品
TWI594758B (zh) 包含雙歧桿菌的組合物、其製備方法及其用途
MX2013006460A (es) Bifidobacterium cect 7765 y su uso en la prevencion y/o tratamiento del sobrepeso, la obesidad y patologias asociadas.
WO2020008149A1 (fr) Utilisation d'une souche de roseburia intestinalis pour la prévention et le traitement de l'inflammation de l'intestin
CN108721337A (zh) 一种预防肿瘤化疗肠道毒性的微生物菌剂
CN113166714A (zh) 包含小克里斯滕森氏菌的克里斯滕森氏菌科细菌及其用途
CN118660712A (zh) 肝脂肪变性的预防或治疗
JP6735338B2 (ja) 腸内細菌のＢｕｔｙｒｉｂａｃｔｅｒ ｉｎｔｅｓｔｉｎｉおよびその使用
CN106852938A (zh) 拟杆菌(Bacteroides)在治疗和预防肥胖相关疾病中的应用
Han et al. Postbiotics ameliorate DSS-induced colitis in mice by regulating gut microbiota, promoting tryptophan metabolism, and activating AhR/IL-22 signaling pathway
EP3889250A1 (en) Phascolarctobacterium faecium for use in the prevention and treatment of obesity and its comorbidities
El-Dalatony et al. Introduction to probiotics and their potential health benefits
Leo et al. Probiotics beverages: An alternative treatment for metabolic syndrome
Ajay et al. Probiotics: Immune Responses and Gut Microbiome
CN106974940B (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
CN106974939B (zh) 厚壁菌类益生菌在治疗和预防肥胖及其相关疾病中的应用
Muntingh Ok, so who wants to colonise my gut?-Overview of Probiotics in certain Gastro-intestinal Disorders
Garssen et al. Immunomodulation by probiotics: a literature survey
Collins et al. Understanding the probiotic
JP2025519401A (ja) ビタミンＢ２及びラクトバチルス・ラムノサス（Ｌａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ）を含む組み合わせ
JP2026507673A (ja) Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ ｌｏｎｇｕｍの菌株およびその使用
CN120478421A (zh) 一种具有改善肠道菌群失调及肠道损伤的合生元制剂及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20260415

Address after: Amsterdam

Applicant after: Kales Life Science Intellectual Property Co., Ltd.

Country or region after: Netherlands

Applicant after: Amsterdam University Medical Center Foundation

Address before: Holland ziegild

Applicant before: Caelus Pharmaceuticals B.V.

Country or region before: Netherlands

Applicant before: Amsterdam University Medical Center Foundation